Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
  • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention concerns formulations of racemic, S(-) or R(+) enantiomers of N-propargyl-1-aminoindan, and especially formula ⁇ tions of the enantiomer R(+) of N-propargyl-1-aminoindan (referred to hereinafter as R(+) PAl) which is a selective irreversible inhibitor of the B- for of the enzyme monoamine oxidase used, for example, for the treatment of Parkinson's disease.
• R(+) PAl is a selective irreversible inhibitor of the B- for of the enzyme monoamine oxidase used, for example, for the treatment of Parkinson's disease.
• MAO monoamine oxidase
• MAO-B the enzyme monoamine oxidase
• GB 1 003 686 discloses a group of benzocycloalkane compounds in which the cycloalkane has from five to seven ring members and is substituted by an N-(alkynylalkyl)amino group, and their use as MAO inhibitors.
• the patent further discloses the use of the subject compounds in admixture with a variety of substances including various alcohols such as a benzyl alcohol, stearyl alcohol, and methanol.
• the patent does not teach how and by what criteria any of the many possible carriers and other ingredients arc selected so as to overcome the stability problem of the product. _ *" > _
• the object of the present invention is to provide stable formula ⁇ tions comprising an effective amount of racemic, S(-) or R(+)-N-proparg- yl-1-aminoindan.
• the abbreviation PAl unless specified otherwise, will be used to denote the enantiomers of N-propargyl- 1-aminoindan, as well as their racemic mixtures.
• a pharmaceutical composition comprising as an active ingredient a therapeuti ⁇ cally effective amount of a compound being a member selected from the group of racemic, S(-), and R(+)-N-propargyl-l-aminoindan or a pharmaceutically acceptable salt thereof, and at least 60% by weight of at least one alcohol being a member selected from the group of pentahydric and hexahydric alcohols.
• the active ingredient is R(+)-N-propargyl-l-aminoindan.
• the composition comprises at least 70% of said at least one alcohol.
• the alcohol used in accordance with of the invention is a member selected from the group of mannitol, xylitol and sorbitol.
• the PAI-comprising composition may further include citric acid, preferably in an amount of 0.5 to 2% by weight.
• compositions according to the invention may further comprise magnesium stearate, preferably in an amount of 0.1 to 0.5% by weight.
• the composition further comprises citric acid in an amount specified above.
• the inclusion of citric acid is optional.
• the composition of the present invention may optionally also include conventional additives such as fillers, lubricants, disintegrants, glidants, flavoring agents, sweeteners, coloring agents, and the like, all as known per se. Examples of fillers which may be used in accordance with the present invention are lactose, starch, microcrystalline cellulose, maltrin and the like.
• compositions of the present invention may be prepared by methods known per se, familiar to those skilled in the art.
• PAl and all other ingredients may be screened and mixed thoroughly in a suitable granulating machine.
• the granulation may occur in the presence of purified water, following which the composition is dried.
• the dry granulate may then be milled, lubricated and compressed into tablets.
• R(+) PAl itself may be prepared, for example, according to the process described in Example 6B of WO95/11016.
• Maltodextrin (Maltrin 150) 36.0 Croscarmellose sodium (Ac-Di-Sol) 2.1
• compositions of the present invention were compared with those known in the prior art.
• two of the above formulations were compared with a formulation described in WO95/11016.
• This formulation as well as those described under Examples 2 and 3 of the present application were subjected to 6 months at 40°C and 75% humidity.
• the percentage of degradants of the active material was assayed at the end of the six month period.
• the following procedure was adopted to determine the degrada ⁇ tion of the formulations prepared.
• the tablets were finely powdered and extracted with a diluent such as a mixture of water, acetonitrile and perchloric acid. An aliquot of the extraction product was injected into an HPLC and eluted using the same mixture as said diluent mixture. The area corresponding to the PAl compound was determined as was that of any other major peak.
• Formulations according to the present invention and others according to the description given in Example 20 of WO95/11016 were prepared containing the ingredients shown in Table 1.
• the formulations described in this Table are designated "PCT" when prepared in accordance with the disclosure in WO95/11016, or by a number which corresponds to the number of the Example in the present application, in which they are described.
• the qualifying symbols of A, B, C or D appearing next to some of these designations denote certain variations in said formulations.
• the percentage of degradation, presented in Table 2 was calculated for all the formulations of Table 1, after storing them for 1 month at 55°C or for 6 months at 40°C and 75% humidity. Those formulations stored according to the latter storing conditions are marked in the Table with an astrix (*). As can be seen from Table 2, the stabilities of all the compositions of the present invention was superior to those of the prior art.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Biomedical Technology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Biophysics (AREA)
• Molecular Biology (AREA)
• Psychology (AREA)
• Pain & Pain Management (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Solid Fuels And Fuel-Associated Substances (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (2)

Family

ID=11068003

Family Applications (1)

Country Status (13)

Cited By (15)

Families Citing this family (39)

Family Cites Families (8)

• 1995
  • 1995-09-20 IL IL11535795A patent/IL115357A/xx not_active IP Right Cessation
• 1996
  • 1996-09-18 DK DK96930344T patent/DK0858328T3/da active
  • 1996-09-18 HU HU9802999A patent/HU225859B1/hu unknown
  • 1996-09-18 AU AU69427/96A patent/AU728524B2/en not_active Expired
  • 1996-09-18 JP JP51411997A patent/JP4108750B2/ja not_active Expired - Lifetime
  • 1996-09-18 AT AT96930344T patent/ATE362755T1/de active
  • 1996-09-18 CA CA002232310A patent/CA2232310C/en not_active Expired - Lifetime
  • 1996-09-18 ES ES96930344T patent/ES2287940T3/es not_active Expired - Lifetime
  • 1996-09-18 WO PCT/IL1996/000115 patent/WO1997012583A2/en not_active Ceased
  • 1996-09-18 EP EP96930344A patent/EP0858328B1/en not_active Expired - Lifetime
  • 1996-09-18 US US09/043,475 patent/US6126968A/en not_active Expired - Lifetime
  • 1996-09-18 PT PT96930344T patent/PT858328E/pt unknown
  • 1996-09-18 DE DE69637096T patent/DE69637096T2/de not_active Expired - Lifetime

Also Published As

Similar Documents

Legal Events